Suppr超能文献

格雷夫斯病患者使用 EQ-5D-5L 的心理测量学特性。

Psychometric properties of EQ-5D-5L for use in patients with Graves' disease.

机构信息

Department of Surgery, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.

Department of Clinical Oncology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.

出版信息

Health Qual Life Outcomes. 2023 Aug 15;21(1):90. doi: 10.1186/s12955-023-02177-z.

Abstract

BACKGROUND

The EQ-5D-5 L is a commonly used generic measure of health. This study aimed to evaluate the psychometric properties of the EQ-5D-5 L in patients with Graves' disease (GD).

METHODS

A prospective cohort of patients with GD recruited at three public hospitals in Hong Kong completed the EQ-5D-5 L and ThyPRO-39 questionnaires at baseline, 1-month, and 6-month follow-ups. Convergent validity was tested by examining the Spearman correlation between EQ-5D-5 L and ThyPRO-39 scores at baseline. 1-month test-retest reliability was assessed by Intraclass Correlation Coefficient (ICC), Gwet's Agreement Coefficient 2 (AC2), and percentage agreement. Responsiveness of EQ-5D-5 L index and EQ-VAS scores was assessed using effect size statistics (standardized effect size [SES] and standardized response mean [SRM]).

RESULTS

Of 125 recruited patients, 101 (80.8%) and 100 (80.0%) patients were followed up at 1- and 6-month, respectively. For convergent validity, there was a moderate negative correlation between EQ-5D-5 L index or EQ-VAS score and ThyPRO-39 overall QoL-impact score (-0.350, -0.451), between EQ-VAS score and composite score (-0.483), and strong negative correlation between EQ-5D-5 L index score and composite score (-0.567). The Gwet's AC2 and percentage agreement were the highest in self-care (0.964 and 0.967), followed by mobility (0.952 and 0.962), usual activities (0.934 and 0.948), pain/discomfort (0.801 and 0.887), and anxiety/depression (0.788 and 0.882). The ICC for the EQ-5D-5 L index and the EQ-VAS was 0.707 and 0.700. For patients who reported having 'worsened' health at 6-month follow-up, the SES and SRM were - 0.66 and - 0.42 for EQ-5D-5 L index and - 1.15 and - 1.00 for EQ-VAS, respectively.

CONCLUSIONS

The EQ-5D-5 L demonstrated convergent validity, test-retest reliability, and responsiveness to worsened health status among patients with GD.

摘要

背景

EQ-5D-5L 是一种常用的通用健康衡量标准。本研究旨在评估 EQ-5D-5L 在格雷夫斯病(GD)患者中的心理测量特性。

方法

在香港的三家公立医院招募了一批 GD 患者进行前瞻性队列研究,这些患者在基线、1 个月和 6 个月的随访中完成了 EQ-5D-5L 和 ThyPRO-39 问卷。通过在基线时检查 EQ-5D-5L 和 ThyPRO-39 评分之间的斯皮尔曼相关关系来测试收敛效度。使用组内相关系数(ICC)、Gwet 的一致性系数 2(AC2)和百分比一致性来评估 1 个月时的重测信度。使用效应量统计(标准化效应量 [SES] 和标准化反应均值 [SRM])评估 EQ-5D-5L 指数和 EQ-VAS 评分的反应性。

结果

在招募的 125 名患者中,分别有 101 名(80.8%)和 100 名(80.0%)患者在 1 个月和 6 个月时进行了随访。对于收敛效度,EQ-5D-5L 指数或 EQ-VAS 评分与 ThyPRO-39 总体生活质量影响评分呈中度负相关(-0.350,-0.451),EQ-VAS 评分与综合评分呈中度负相关(-0.483),EQ-5D-5L 指数评分与综合评分呈强负相关(-0.567)。自我护理的 Gwet 的 AC2 和百分比一致性最高(0.964 和 0.967),其次是移动性(0.952 和 0.962)、日常活动(0.934 和 0.948)、疼痛/不适(0.801 和 0.887)和焦虑/抑郁(0.788 和 0.882)。EQ-5D-5L 指数和 EQ-VAS 的 ICC 分别为 0.707 和 0.700。对于在 6 个月随访时报告健康状况恶化的患者,EQ-5D-5L 指数和 EQ-VAS 的 SES 和 SRM 分别为-0.66 和-0.42 和-1.15 和-1.00。

结论

EQ-5D-5L 在 GD 患者中表现出收敛效度、重测信度和对健康状况恶化的反应性。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验